학술논문
Efficacy and safety of oral immunotherapy with AR101 in European children with a peanut allergy (ARTEMIS): a multicentre, double-blind, randomised, placebo-controlled phase 3 trial
Document Type
Article
Author
O'B Hourihane, Jonathan; Beyer, Kirsten; Abbas, Allyah; Fernández-Rivas, Montserrat; Turner, Paul J; Blumchen, Katharina; Nilsson, Caroline; Ibáñez, Maria D; Deschildre, Antoine; Muraro, Antonella; Sharma, Vibha; Erlewyn-Lajeunesse, Michel; Zubeldia, José Manuel; De Blay, Frederic; Sauvage, Christine D; Byrne, Aideen; Chapman, John; Boralevi, Franck; DunnGalvin, Audrey; O'Neill, Charmaine; Norval, David; Vereda, Andrea; Skeel, Ben; Adelman, Daniel C; du Toit, George
Source
The Lancet Child & Adolescent Health; October 2020, Vol. 4 Issue: 10 p728-739, 12p
Subject
Language
ISSN
23524642; 23524650
Abstract
Peanut allergy is the leading cause of food-related anaphylaxis. Current management options can negatively affect food allergy-related quality of life. We aimed to investigate the efficacy of an investigational oral biologic drug (AR101).